Literature DB >> 12467233

Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines.

L He1, C P Yang, S B Horwitz.   

Abstract

The epothilones (Epos) are a group of natural products isolated from the myxobacterium, Sorangium cellulosum. They have a mechanism of action similar to that of Taxol, i.e., they stabilize microtubules and induce the formation of microtubule bundles in cells. Because they are simpler in structure than Taxol and preserve their activity in P-glycoprotein-expressing cells, they are being studied as potential antitumor drugs. In this work, a series of Epo-resistant A549 and HeLa cell lines have been selected and analyzed. Class I beta-tubulin, the major isotype of beta-tubulin in these Epo-resistant cell lines, has been sequenced in a search for mutations. In the Epo B-resistant A549 cells, there is a mutation at beta 292 from Gln to Glu, in the Epo A-resistant HeLa cell line there is a mutation at beta 173 from Pro to Ala, and in the Epo B-resistant HeLa cell line there is a heterozygous mutation at beta 422 from Tyr to a mixture of Tyr and Cys. These mutations are close to the M-loop, the nucleotide-binding site, and the microtubule-associated protein binding sites, respectively. It is likely that these mutations in beta-tubulin provide cells with a mechanism of resistance to the Epos and taxanes. Among these resistant cell lines, A549.EpoB40 is hypersensitive to microtubule-destabilizing drugs, such as vinblastine and colchicine, and HeLa.EpoB1.8 is dependent on the Epos or taxanes for growth. Our studies provide evidence that the M-loop, the GTP binding site, and the microtubule-associated protein binding sites at the COOH terminus in beta-tubulin are critical for the regulation of microtubule stability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12467233

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  37 in total

1.  A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation.

Authors:  Rajat Bhattacharya; Fernando Cabral
Journal:  Mol Biol Cell       Date:  2004-04-30       Impact factor: 4.138

2.  Microplate spectrophotometry for high-throughput screening of cytotoxic molecules.

Authors:  C Tomelleri; C Dalla Pellegrina; R Chignola
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

3.  Taxol allosterically alters the dynamics of the tubulin dimer and increases the flexibility of microtubules.

Authors:  Arpita Mitra; David Sept
Journal:  Biophys J       Date:  2008-07-11       Impact factor: 4.033

Review 4.  Microtubule targeting agents: from biophysics to proteomics.

Authors:  D Calligaris; P Verdier-Pinard; F Devred; C Villard; D Braguer; Daniel Lafitte
Journal:  Cell Mol Life Sci       Date:  2010-01-28       Impact factor: 9.261

5.  Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.

Authors:  Yuefang Wang; Aurora O'Brate; Wei Zhou; Paraskevi Giannakakou
Journal:  Cell Cycle       Date:  2005-12-18       Impact factor: 4.534

6.  Epothilone B enhances surface EpCAM expression in ovarian cancer Hey cells.

Authors:  Shohreh Shahabi; Chia-Ping Huang Yang; Gary L Goldberg; Susan Band Horwitz
Journal:  Gynecol Oncol       Date:  2010-08-02       Impact factor: 5.482

7.  Human liver microsomal metabolism of (+)-discodermolide.

Authors:  Yun Fan; Emanuel M Schreiber; Billy W Day
Journal:  J Nat Prod       Date:  2009-10       Impact factor: 4.050

8.  Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.

Authors:  Chun Hei Antonio Cheung; Su-Ying Wu; Tian-Ren Lee; Chi-Yen Chang; Jian-Sung Wu; Hsing-Pang Hsieh; Jang-Yang Chang
Journal:  PLoS One       Date:  2010-09-03       Impact factor: 3.240

9.  The roles of beta-tubulin mutations and isotype expression in acquired drug resistance.

Authors:  J Torin Huzil; Ke Chen; Lukasz Kurgan; Jack A Tuszynski
Journal:  Cancer Inform       Date:  2007-04-27

10.  Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer.

Authors:  Shannon Puhalla; Adam Brufsky
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.